By Drs Ian Nisbet & Walid Azar
As published in Pharmaphorum – 14 May 2026
Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to solid tumours, perceptions about their effectiveness often lag behind the emerging scientific evidence.
In particular, Chimeric Antigen Receptor – Natural Killer (CAR-NK) […]
Today on World Ovarian Cancer Day, we pause to listen, reflect, and amplify the voices of those who have experienced ovarian cancer first-hand. At Cartherics, this day is a powerful reminder of why we do what we do – driving awareness and advancing new treatment options that offer real hope for women.
We’re honoured to share […]
April 9 (US ET), 2026 – Melbourne, Australia, and Tampa, FL – Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership.
The companies […]
By Wholesale Investor
In the high-octane world of biotechnology, success is often measured by the narrowest of margins. But for Dr. Ian Nisbet, CEO of Melbourne-based Cartherics Pty Ltd, the mission is defined by a gap so large it has become a “tragic” outlier in modern medicine: the chronic underfunding of women’s health.
Ovarian cancer, often called […]
Cartherics is pleased to share Dr Ian Nisbet’s presentation at the Emergence Investment Conference in Sydney, where he outlined the Company’s strategy, progress and vision for transforming women’s health through pioneering cellular immunotherapies.
Speaking to an audience of investors and industry leaders, Dr Nisbet highlighted Cartherics’ unique focus on developing off-the-shelf cell therapies designed specifically to […]
Cartherics is pleased to announce that Professor Alan Trounson AO, Deputy Chair, will deliver an invited lecture at King Abdullah University of Science and Technology (KAUST) titled: A Platform Technology for Immune Targeting Cancer and Endometriosis – A Women’s Health Focus. The lecture will take place on February 4, at 10.30am (AST).
In this lecture, Professor […]
Cartherics is pleased to announce that Dr Madeline Cao, Head of Manufacturing Development and Dr Walid Azar, Chief Scientific Officer, will present at the upcoming ANZ Biologics Festival in Melbourne, showcasing Cartherics’ progress in building a discovery-to-clinic engine for scalable, off-the-shelf cell therapies.
Dr. Cao will deliver a presentation titled, ‘Off-the-Shelf’ Immuno-Cell Therapies: Manufacturing […]
Melbourne, Australia, 29 January 2026 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is pleased to announce the granting of a second patent in China for “Genetically modified cells and uses thereof” by the Chinese Patent Office.
This patent extends the Company’s […]
With the end of the year fast approaching, it is timely to take a step back and reflect on the challenges and achievements for 2025.
We began the year with optimism and momentum, having completed a major financing round late in 2024 (thanks to our incredible group of investors). We were preparing for filing an IND […]
Melbourne, Australia, 16 December 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer and endometriosis.
Stay informed about our latest news and developments
© Copyright 2022 – 2026| Cartherics Pty Ltd
